The Inquiry Committee has lifted the registrant’s suspension, which had previously been in place for an indefinite period on July 3, 2019. Pursuant to Section 32.2(4)(b)(ii) of the Health Professions Act, the Inquiry Committee has reached an Agreement with the pharmacist registrant whereby the pharmacist registrant consented to terms including, but not limited to, the following:
-
To comply with any and all treatment plans as recommended by his medical providers.
-
To comply with any and all work plans as advised by his medical providers and/or employers.
-
To comply with every term of his Relapse Prevention Agreement (“RPA”).
-
In the event of any interruption to the agreed monitoring schedule set out in the RPA, the Registrant will advise the College of the interruption as soon as possible and provide an explanation for the interruption.
-
The Registrant will inform the College in writing, via e-mail, of his places of work as a pharmacist and report any changes to the location of his work within 48 hours of such change. A reportable change to the Registrant’s place of work contemplates both commencement and termination of work.
-
To return to follow any graduated return to work schedules as recommended by his medical providers.
-
Prior to the commencement of work at any pharmacy, the Registrant shall:
- Disclose to the pharmacy manager and/or employer any gradual return to work schedule, as required by his medical providers;
- Disclose to the pharmacy manager and/or employer terms of this consent agreement;
- Ensure that any pharmacy manager and/or employer with whom the Registrant secures work in a pharmacy submits a written statement to the College declaring they have reviewed terms of the Registrant’s Consent Agreement and gradual return to work schedule. This statement must be received within 48 hours of securing work and/or within 48 hours of any change of pharmacy manager at the Registrant’s place of work.
-
To voluntarily stop working as a pharmacist and self-report to the College in the event that his medical condition may materially impair or hinder his performance and/or fitness to practice as a pharmacist.
This Agreement will remain in place until such time as the Registrant’s physician states otherwise. The pharmacist registrant’s name has been withheld pursuant to section 39.3(4)(a) of the Health Professions Act.
July 3, 2019
(May 30, 2022 - Suspension Ended)
The Inquiry Committee, pursuant to section 32.2(4)(b)(ii) of the Health Professions Act, has reached an agreement with the pharmacist registrant to voluntarily suspend the registration as a pharmacist effective July 3, 2019. The agreement remains in effect until further notice. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant’s name has been withheld pursuant to section 39.3(4)(a) of the Health Professions Act.